Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs
Nucleic Acid Therapeutics · 01.12.2022 · 32 (6) · 507-512
DOI: 10.1089/nat.2022.0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 05.12.2022. Verfasst von Alessandro Boianelli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZenec…. Hauptthemen laut MEDLINE: RNA, Small Interfering. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Small interfering RNAs (siRNAs) with N -acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases. Understanding how pharmacokinetics and pharmacodynamics translate is pivotal for in vivo study design and human dose prediction. However, the literature is sparse on translational data for this modality, and pharmacokinetics in the liver is seldom measured. To overcome these difficulties, we collected time-course biomarker data for 11 GalNAc–siRNAs in various species and applied the kinetic-pharmacodynamic modeling approach to estimate the biophase (liver) half-life and the potency. Our analysis indicates that the biophase half-life is 0.6–3 weeks in mouse, 1–8 weeks in monkey, and 1.5–14 weeks in human. For individual siRNAs, the biophase half-life is 1–8 times longer in human than in mouse, and generally 1–3 times longer in human than in monkey. The analysis indicates that the siRNAs are more potent in human than in mouse and monkey.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Quantitative Biology SE, Data Sciences and Quantitative Biology, Discovery Sciences, AstraZeneca, Gothenburg, Sweden.
- Oligonucleotide Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Department of Biomedical Engineering, Linköping University, Linköping, Sweden.
ORCID-Profile: Anders Dahlén, Peter Gennemark
Zitieren
APA
Boianelli, A., Aoki, Y., Ivanov, M., Dahlén, A., & Gennemark, P. (2022). Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs. Nucleic Acid Therapeutics, 32(6), 507-512. https://doi.org/10.1089/nat.2022.0010
Vancouver
Boianelli A, Aoki Y, Ivanov M, Dahlén A, Gennemark P. Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs. Nucleic Acid Therapeutics. 2022;32(6):507-512. doi:10.1089/nat.2022.0010
BibTeX
@article{Boianelli2022,
author = {Boianelli, Alessandro and Aoki, Yasunori and Ivanov, Maxim and Dahlén, Anders and Gennemark, Peter},
title = {Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs},
journal = {Nucleic Acid Therapeutics},
year = {2022},
volume = {32},
number = {6},
pages = {507--512},
doi = {10.1089/nat.2022.0010}
}
EUVIMED